

10. (currently amended). The method of claim 10, wherein the botulinum neurotoxin is administered to the anterior pituitary.

11. (currently amended). The method of claim 1 wherein the botulinum neurotoxin is administered to the posterior pituitary.

12. (original). The method of claim 1, wherein the intracranial administration step comprises the step of implantation of a controlled release botulinum toxin system.

13. (currently amended). A method for treating an endocrine condition~~disorder~~, the method comprising the step of intracranial administration of a therapeutically effective amount of a botulinum toxin type A to the hypothalamus or pituitary of a patient, thereby alleviating a symptom of an endocrine condition~~disorder~~ by reducing a secretion of a hypothalamic or pituitary hormone or releasing hormone, wherein the endocrine condition is selected from the group consisting of gametogenesis, menstruation, acromegaly, gigantism, Cushing's disease, hypergonadism and hyperthyroidism.

14. (cancelled).

15. (cancelled)..

16. (cancelled).

17. (currently amended). A method for treating an endocrine condition~~disorder~~, the method comprising the steps of:

(a) selecting a neurotoxin with hypothalamic releasing hormone suppressant activity: